AstraZeneca PLC (AZN)vsICU Medical Inc (ICUI)
AZN
AstraZeneca PLC
$185.95
-1.94%
HEALTHCARE · Cap: $282.69B
ICUI
ICU Medical Inc
$136.61
+1.25%
HEALTHCARE · Cap: $3.55B
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 2702% more annual revenue ($60.44B vs $2.16B). AZN leads profitability with a 17.2% profit margin vs 2.1%. ICUI appears more attractively valued with a PEG of 0.08. AZN earns a higher WallStSmart Score of 64/100 (C+).
AZN
Buy64
out of 100
Grade: C+
ICUI
Hold48
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+8.2%
Fair Value
$194.77
Current Price
$185.95
$8.82 discount
Margin of Safety
+54.6%
Fair Value
$325.54
Current Price
$136.61
$188.93 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 22 in profit
Strong operational efficiency at 27.9%
Generating 1.8B in free cash flow
Growing faster than its price suggests
Reasonable price relative to book value
Areas to Watch
Moderate valuation
Distress zone — elevated risk
Distress zone — elevated risk
ROE of 2.2% — below average capital efficiency
2.1% margin — thin
Premium valuation, high expectations priced in
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.2% and operating margin at 27.9%. Revenue growth of 12.5% demonstrates continued momentum.
Bull Case : ICUI
The strongest argument for ICUI centers on PEG Ratio, Price/Book. PEG of 0.08 suggests the stock is reasonably priced for its growth.
Bear Case : AZN
The primary concerns for AZN are P/E Ratio, Altman Z-Score.
Bear Case : ICUI
The primary concerns for ICUI are Altman Z-Score, Return on Equity, Profit Margin. A P/E of 76.5x leaves little room for execution misses. Thin 2.1% margins leave little buffer for downturns.
Key Dynamics to Monitor
AZN profiles as a mature stock while ICUI is a value play — different risk/reward profiles.
ICUI carries more volatility with a beta of 0.78 — expect wider price swings.
AZN is growing revenue faster at 12.5% — sustainability is the question.
AZN generates stronger free cash flow (1.8B), providing more financial flexibility.
Bottom Line
AZN scores higher overall (64/100 vs 48/100), backed by strong 17.2% margins and 12.5% revenue growth. ICUI offers better value entry with a 54.6% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
ICU Medical Inc
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
ICU Medical, Inc. develops, manufactures and sells medical devices used in infusion therapy and critical care applications worldwide. The company is headquartered in San Clemente, California.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?